Last reviewed 2026-04-23 · How we verify

placebo plus chemoradiotherapy

This drug works by combining a placebo with chemoradiotherapy to treat cancer.

This drug works by combining a placebo with chemoradiotherapy to treat cancer. Used for Metastatic cancer.

At a glance

Mechanism of action

Chemoradiotherapy involves the use of chemotherapy and radiation to kill cancer cells. The placebo serves as a control group in clinical trials, allowing researchers to compare the effectiveness of the treatment.

Approved indications

• Metastatic cancer

Common side effects

• Nausea
• Fatigue
• Hair loss

Key clinical trials

• Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
• Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma (PHASE2)
• Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer (PHASE2)
• A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer (PHASE2, PHASE3)
• A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (PHASE3)
• High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer (PHASE3)
• A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients (PHASE3)
• Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.